Features of use of dapagliflozin in thetreatment of patients with type 2 diabetes mellitus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Clinical studies published to date have shown that dapagliflozin is safe and effective for patients with type 2 diabetes mellitus, both as monotherapy and in combination with other oral hypoglycemic agents [9]. Recent publications summarizing the 4-year clinical experience confirms these results. Dapagliflozin is effective both at early and at later stages of type 2 diabetes mellitus.

Full Text

Restricted Access

About the authors

M. B Antsiferov

SBHCI “Endocrinologicla Dispensary" of Moscow Healthcare Department

MD, Prof., Chief Physician

References

  1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 7-е изд. Сахарный диабет. 2015;18(1S):1-112.
  2. Дедов И.И., Шестакова М.В. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально-значимыми заболеваниями 2007-2012 гг.». Сахарный диабет. 2013;спецвыпуск:2-48.
  3. Meng W., Ellsworth B.A., NIrsch I., et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) Inhibitor for the treatment of type 2diabetes. J. Med. Chem. 2008;51:1145-49.
  4. Bailey C.J., Day C. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br. J. Diabetes Vasc. Dis. 2010;10:193-99.
  5. Santer R., Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol. 2010;5:133-41.
  6. Kanai Y., Lee W.-S., You G., et al. The human kidney low affinity Na+/glucose cotransporter SGLT2: Delineation of the major renal reabsorptive mechanism for d-glucose. J. Clin. invest.1994;93:397-404.
  7. de Paoli P., Battistin S., Jus A., Reitano M., Villalta D., De Marchi S., Cecchin E., Basile A., Santini G. immunological characterization of renal glycosuria patients. Clin. Exp. immunol. 1984;56:289-94.
  8. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-49.
  9. Инструкция по медицинскому применению лекарственного препарата Форсига с учетом изменений 1-4. Регистрационное удостоверение № ЛП 002596 от 21.08.14.
  10. AZ-Мост Медицинский портал для специалистов. [Электронный ресурс], 12 сентября 2016. URL: http://www.az-most.ru/news/forxiga-new-horizon.html
  11. DeFronzo R.A., Davidson J.A., Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 2012;14(1):5-14.
  12. Kaku K., Kiyosue A., Inoue S., Ueda N., Tokudome T., Yang J., Langkilde A.M. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes. Metab. 2014;16:1102-10.
  13. Bailey C.J., Iqbal N., TJoen C., List J.F. Dapagliflozin monotherapy in drugnaive patients with diabetes: a randomized-controlled trial of lowdose range. Diabetes Obes. Metab. 2012;14:951-59.
  14. Ferrannini E., Ramos S.J., Salsali A., Tang W., List J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-24.
  15. Ji L., Ma J., Li H., Mansfield T.A., T'Joen C.L., Iqbal N., et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin. Ther. 2014;36:84-100.
  16. List J.F., Woo V., Morales E., Tang W., Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-57.
  17. Kaku K., Inoue S., Matsuoka O., Kiyosue A., Azuma H., Hayashi N., et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo- ontrolled trial. Diabetes Obes. Metab. 2013;15:432-40.
  18. Bailey C.J., Gross J.L., Pieters A., Bastien A., List J.F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-33.
  19. Henry R.R., Murray A.V., Marmolejo M.H., Hennicken D., Ptaszynska A., List J.F. Dapaglifl ozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 2012;66(5):446-56.
  20. Nauck M.A., Del Prato S., Meier J.J., Duran-Garcia S., Rohwedder K., Elze M., Parikh S.J. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22.
  21. Del Prato S., Nauck M., Duran-Garcia S., Maffei L., Rohwedder K., Theuerkauf A., Parikh S. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes. Metab. 2015;17:581-90.
  22. Nauck M.A., Del Prato S., Meier J.J., et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22.
  23. Bolinder J., Ljunggren Ö., Johansson L., et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus nadequately controlled on metformin. Diabetes Obes. Metab. 2014;16(2):159-69.
  24. Sjöström C.D., Johansson P, Ptaszynska A., List J., Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab. Vasc. Dis. Res. 2015;12(5):352-58.
  25. Yavin Y., Mansfield T.A., Ptaszynska A., Johnsson K., Parikh S., Johnsson E. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther. 2016:7(1):125-37.
  26. Sonesson C., Johansson P.A., Johnsson E., Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc. Diabetol. 2016;15:37.
  27. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the incidence of Cardiovascular Events (DECLARE-TiMi58). https://clinicaltrials. gov/ct2/show/NCT01730534.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media